# A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors

> **NCT07387874** · — · ACTIVE_NOT_RECRUITING · sponsor: **Lixiaoling** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent or Metastatic Solid Tumors

## Interventions

- **DRUG:** Trastuzumab Rezetecan
- **DRUG:** Other Drugs

## Key facts

- **NCT ID:** NCT07387874
- **Lead sponsor:** Lixiaoling
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2027-07
- **Final completion:** 2028-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07387874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07387874, "A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07387874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*